Top Page
Gilead Sciences
(NASDAQ:GILD)
Gilead Sciences (GILD) vs. SPDR S&P 500 ETF (SPY)
Gilead Sciences Business Overview & Revenue Model
Gilead Sciences Key Performance Indicators (KPIs)
Analyzes income from different sources, highlighting which areas are driving growth and which might be underperforming, crucial for assessing the company's financial health and strategic focus.
Main Street DataGilead Sciences Earnings Call Summary
Gilead Sciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.09B | 28.75B | 27.12B | 27.28B | 27.30B | 24.69B |
| Gross Profit | 22.89B | 22.50B | 20.62B | 21.62B | 20.70B | 20.12B |
| EBITDA | 13.67B | 4.43B | 10.50B | 8.85B | 11.33B | 4.13B |
| Net Income | 8.11B | 480.00M | 5.67B | 4.59B | 6.22B | 123.00M |
Balance Sheet | ||||||
| Total Assets | 58.53B | 58.99B | 62.13B | 63.17B | 67.95B | 68.41B |
| Cash, Cash Equivalents and Short-Term Investments | 7.35B | 11.57B | 7.26B | 6.38B | 6.52B | 7.41B |
| Total Debt | 24.94B | 26.71B | 24.99B | 25.23B | 26.70B | 31.40B |
| Total Liabilities | 37.08B | 39.75B | 39.38B | 41.96B | 46.89B | 50.19B |
| Stockholders Equity | 21.54B | 19.33B | 22.83B | 21.24B | 21.07B | 18.20B |
Cash Flow | ||||||
| Free Cash Flow | 9.16B | 10.30B | 7.42B | 8.34B | 10.80B | 7.52B |
| Operating Cash Flow | 9.67B | 10.83B | 8.01B | 9.07B | 11.38B | 8.17B |
| Investing Cash Flow | -3.18B | -3.45B | -2.27B | -2.47B | -3.13B | -14.62B |
| Financing Cash Flow | -4.22B | -3.43B | -5.13B | -6.47B | -8.88B | 770.00M |
Gilead Sciences Technical Analysis
Gilead Sciences Risk Analysis
Gilead Sciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $235.92B | 12.57 | 39.51% | 3.41% | 1.59% | 58.02% | |
77 Outperform | $158.89B | 19.70 | 40.53% | 2.62% | 2.76% | 6407.19% | |
77 Outperform | $184.38B | 26.59 | 81.71% | 2.83% | 11.03% | 65.22% | |
76 Outperform | $120.73B | 12.60 | 8.39% | 4.46% | -9.32% | 120.62% | |
69 Neutral | $93.22B | 15.89 | 33.84% | 5.42% | 1.26% | ― | |
68 Neutral | $141.46B | 14.83 | 10.59% | 7.05% | 4.44% | 128.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Gilead Sciences Corporate Events
Gilead Sciences’ latest earnings call conveyed a positive sentiment, primarily driven by robust growth in its HIV portfolio and the successful launch of new products like Yeztugo. Despite facing challenges in the oncology and cell therapy segments, the company remains optimistic about its revenue expectations, thanks to strong commercial execution and strategic advancements.
Gilead Sciences, Inc. is a biopharmaceutical company specializing in innovative medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, cancer, and inflammation, with operations in over 35 countries and headquartered in Foster City, California.
Gilead Sciences recently updated its clinical study titled ‘An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1; Substudy-04: GS-1219.’ This study aims to assess the safety, pharmacokinetics, and antiviral activity of the novel drug GS-1219 in individuals with HIV-1, contributing to the broader understanding of antiretroviral treatments.
Gilead Sciences, in collaboration with Arcus Biosciences, recently completed a clinical study titled ‘A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.’ The study aimed to assess the antitumor activity and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer, a significant area of unmet medical need.
On October 6, 2025, Gilead Sciences announced settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. to resolve patent litigations concerning generic versions of Biktarvy®. These agreements prevent the entry of generic Biktarvy tablets in the U.S. market before April 1, 2036, securing Gilead’s market position and patent protection for this product.
The most recent analyst rating on (GILD) stock is a Buy with a $133.00 price target. To see the full list of analyst forecasts on Gilead Sciences stock, see the GILD Stock Forecast page.
Gilead Sciences is currently conducting a clinical study titled ‘Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta.’ The study aims to assess the safety and effectiveness of GS-4321, a potential treatment for Chronic Hepatitis Delta (CHD). The study is significant as it explores new therapeutic options for CHD, a condition with limited treatment options.
Gilead Sciences is conducting a Phase 2/3 open-label study titled ‘A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1.’ The study aims to assess the pharmacokinetics, safety, and antiviral activity of the combination drug Bictegravir/Lenacapavir (BIC/LEN) in virologically suppressed children and adolescents with HIV-1. This research is significant as it targets a younger demographic that requires tailored HIV treatment options.
Study Overview: Gilead Sciences is conducting a Phase 3 clinical trial titled ‘A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy.’ The study aims to evaluate the efficacy of sacituzumab govitecan (SG) compared to the treatment of physician’s choice (TPC) in improving progression-free survival and overall survival in patients with endometrial cancer.
Gilead Sciences is currently conducting a Phase 3 clinical study titled ‘AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.’ The study aims to assess the efficacy of Seladelpar in improving clinical outcomes for patients suffering from PBC and compensated cirrhosis, a chronic liver disease. This research is significant as it could lead to new treatment options for this condition.
Gilead Sciences is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Once-Yearly Intramuscular Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) in People With an Indication for PrEP’. The study aims to assess the safety, tolerability, and pharmacokinetics of lenacapavir, a drug intended for preventing HIV in individuals at risk. This study is significant as it explores a once-yearly injection option, potentially simplifying PrEP regimens.
Study Overview: Gilead Sciences is conducting a Phase 3 study titled A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy. The study aims to evaluate the effectiveness and safety of sacituzumab govitecan-hziy combined with pembrolizumab compared to the standard treatment options in patients with triple negative breast cancer post-surgery and pre-surgical treatment.
Gilead Sciences is initiating a Phase 1 clinical study titled ‘A Phase 1 Study to Evaluate the Safety and Tolerability of GS-5319 in Adults With MTAP-deleted Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, and optimal dosing of GS-5319, a drug targeting advanced solid tumors with a specific gene alteration. This gene alteration affects the production of the MTAP enzyme, which is crucial for normal cell growth.
Gilead Sciences is conducting a pivotal Phase 3 study titled A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study aims to evaluate the efficacy of sacituzumab govitecan (SG) compared to standard treatments in improving objective response rates and overall survival in patients with ES-SCLC, a significant area of unmet medical need.
Gilead Sciences, in collaboration with Arcus Biosciences, is conducting a Phase 2 clinical study titled ‘VELOCITY-Lung’ to evaluate the safety and efficacy of novel treatment combinations in patients with lung cancer. This study aims to assess the objective response rate and complete pathological response rate in different substudies involving patients with metastatic and resectable non-small-cell lung cancer (NSCLC).
Gilead Sciences is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC). The study aims to evaluate the efficacy of GS-1427 in achieving a clinical response in patients with moderate to severe ulcerative colitis by comparing it to a placebo over a 12-week period.
Gilead Sciences, in collaboration with Arcus Biosciences, recently updated their clinical study titled A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies. The study aims to assess the safety, tolerability, and clinical activity of AB308 combined with zimberelimab (AB122) in patients with various advanced cancers, including non-small cell lung cancer and melanoma. This research is significant as it explores new treatment options for challenging malignancies.
Gilead Sciences is currently conducting a Phase 3 clinical study titled ‘A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations.’ The study aims to compare the effectiveness of zimberelimab and domvanalimab combined with chemotherapy against pembrolizumab with chemotherapy in improving overall survival for patients with untreated metastatic non-small cell lung cancer.
Gilead Sciences is currently recruiting participants for a clinical study titled ‘An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1 Substudy-05: GS-3242’. The study aims to assess the safety and effectiveness of novel antiretrovirals, specifically GS-3242, in individuals living with HIV-1. This research is significant as it explores new treatment options for managing HIV-1 infection.
Gilead Sciences, in collaboration with Eisai Korea Inc., is conducting a Phase 4 clinical study titled A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice. The study aims to assess the effectiveness of filgotinib in achieving clinical remission in patients by Week 10 or 22, highlighting its potential significance in treating ulcerative colitis.
Gilead Sciences, in collaboration with Merck Sharp & Dohme LLC, is conducting a Phase 3 clinical study titled ‘An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)’. The study aims to compare the efficacy of pembrolizumab combined with sacituzumab govitecan against pembrolizumab alone in treating metastatic non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of 50% or higher, focusing on progression-free survival and overall survival.
Gilead Sciences, in collaboration with Merck Sharp & Dohme LLC, is currently conducting a Phase 3 clinical study titled ‘An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03).’ The study aims to evaluate the efficacy of pembrolizumab combined with sacituzumab govitecan compared to pembrolizumab alone in improving progression-free survival and overall survival in patients with metastatic non-small cell lung cancer with a PD-L1 tumor proportion score of 50% or higher.
In a significant advancement for cancer treatment, Gilead Sciences and Arcus Biosciences are conducting a Phase 3 study titled A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations. The study aims to compare the overall survival rates of patients receiving zimberelimab and domvanalimab in combination with chemotherapy against those receiving pembrolizumab with chemotherapy.
Gilead Sciences is conducting a study titled ‘An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1 Substudy-05: GS-3242.’ The study aims to assess the safety and effectiveness of a new antiretroviral drug, GS-3242, in individuals living with HIV-1. This study is significant as it contributes to the ongoing efforts to improve HIV treatment options.
Study Overview: Gilead Sciences, in collaboration with Eisai Korea Inc., is conducting a Phase 4 clinical study titled A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice. The study aims to assess the efficacy of filgotinib in achieving clinical remission in patients with ulcerative colitis, highlighting its potential significance in routine clinical settings.
Gilead Sciences, in collaboration with Merck Sharp & Dohme LLC, is conducting a Phase 3 clinical study titled ‘An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)’. The study aims to compare the effectiveness of pembrolizumab combined with sacituzumab govitecan against pembrolizumab alone in improving progression-free survival and overall survival in patients with metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression.
On August 10, 2025, Gilead Sciences announced the appointment of Erin Burkhart as Senior Vice President, Controllership and principal accounting officer, effective September 22, 2025. Ms. Burkhart, with extensive experience in accounting roles at BioMarin Pharmaceutical and Eli Lilly, will succeed Diane E. Wilfong, who will step down on the transition date.
The most recent analyst rating on (GILD) stock is a Hold with a $100.00 price target. To see the full list of analyst forecasts on Gilead Sciences stock, see the GILD Stock Forecast page.
Gilead Sciences is conducting a Phase 3 clinical study titled ‘A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.’ The study aims to evaluate the effectiveness and safety of sacituzumab govitecan-hziy combined with pembrolizumab compared to the treatment of physician’s choice in patients with triple negative breast cancer that remains after surgery and pre-surgical treatment.
Gilead Sciences’ recent earnings call conveyed a positive sentiment, underscored by impressive growth in key product areas and successful new product launches. The company showcased strong performance in the HIV prevention and oncology segments, despite facing challenges in Veklury and cell therapy sales. The robust performance of the base business played a crucial role in offsetting these declines, painting an overall optimistic picture for the company.
Gilead Sciences is conducting a clinical study titled ‘A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer.’ The study aims to evaluate the safety, tolerability, and effectiveness of sacituzumab govitecan-hziy (SG) in treating advanced triple-negative breast cancer (TNBC). This research is significant as it explores alternative dosing schedules to potentially improve patient outcomes.
Gilead Sciences is currently recruiting participants for a pivotal Phase 3 clinical study titled ‘A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)’. The study aims to evaluate the efficacy of sacituzumab govitecan (SG) compared to standard treatments in improving the objective response rate and overall survival in patients with ES-SCLC.
The clinical study titled ‘A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)’ aims to assess the efficacy and safety of various treatment combinations in patients with metastatic or locally advanced breast cancer. This study is significant as it explores new therapeutic avenues for different breast cancer subtypes, potentially improving patient outcomes.
Gilead Sciences and Arcus Biosciences are collaborating on a clinical study titled A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer. The study aims to assess the antitumor activity and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer, a significant area of unmet medical need.
The clinical study titled ‘A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)’ aims to assess the safety and preliminary clinical activity of various treatment combinations, with and without chemotherapy, in patients with advanced gastric, GEJ, and esophageal adenocarcinoma. This study is significant as it explores potential new treatment options for these challenging cancers.
Gilead Sciences, Inc. is a biopharmaceutical company focused on advancing innovative medicines to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, cancer, and inflammation, with operations in over 35 countries worldwide. In the second quarter of 2025, Gilead Sciences reported a 2% increase in total revenue, reaching $7.1 billion, driven by higher sales in HIV, Livdelzi, and Trodelvy products, despite a decline in Veklury sales due to lower COVID-19 hospitalizations. The company also achieved a significant milestone with the FDA approval of Yeztugo, the first twice-yearly HIV prevention option. Key financial metrics for the quarter included a diluted EPS of $1.56, up from $1.29 in the same period last year, and a non-GAAP diluted EPS of $2.01, remaining flat year-over-year. Gilead’s cash reserves stood at $7.1 billion as of June 30, 2025, down from $10.0 billion at the end of 2024, with operating cash flow generation of $827 million. Looking ahead, Gilead has raised its revenue and earnings guidance for the year, reflecting confidence in continued innovation and growth across its core therapeutic areas.